Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 24;6(1):112-127.
doi: 10.20517/evcna.2024.90. eCollection 2025.

Extracellular vesicle-mediated chemoresistance in breast cancer: focus on miRNA cargo

Affiliations
Review

Extracellular vesicle-mediated chemoresistance in breast cancer: focus on miRNA cargo

Maria Chiara Ciferri et al. Extracell Vesicles Circ Nucl Acids. .

Abstract

The role of extracellular vesicles (EVs) in mediating chemoresistance has gained significant attention due to their ability to transfer bioactive molecules between drug-resistant and drug-sensitive cells. In particular, they have been demonstrated to play an active part in breast cancer chemoresistance by the horizontal transfer of genetic and protein material. This review highlights the role of EVs, particularly their miRNA cargo, in driving drug resistance in breast cancer. EVs derived from chemoresistant cells carry miRNAs and lncRNAs, which are known to modulate gene networks involved in cell proliferation and survival. These cargo molecules suppress apoptosis by targeting pro-apoptotic genes like PTEN and BIM, promote epithelial-mesenchymal transition (EMT) through the regulation of pathways such as TGF-β and Wnt/b-catenin, and contribute to tumor growth and resistance by enhancing angiogenesis and modulating the tumor microenvironment. Beyond RNA-mediated effects, EVs also transfer functional proteins, including P-glycoprotein and Hsp70, which impact cellular metabolism and survival pathways. Our findings underscore the significance of EVs in breast cancer chemoresistance, suggesting their potential involvement as possible prognostic factors to predict therapy response and as therapeutic targets in combination with usual therapy.

Keywords: Breast cancer; chemotherapy; circulating EVs; drug resistance.

PubMed Disclaimer

Conflict of interest statement

All authors declared that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Main molecular pathways involved in chemoresistance spreading related to EV-cargo. EV: extracellular vesicle.

References

    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. doi: 10.3322/CAAC.21820. - DOI - PubMed
    1. Passaro A, Al Bakir M, Hamilton EG, et al. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024;187:1617–35. doi: 10.1016/J.CELL.2024.02.041. - DOI - PMC - PubMed
    1. Raghani NR, Chorawala MR, Mahadik M, Patel RB, Prajapati BG, Parekh PS. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies. Med Oncol. 2024:41. doi: 10.1007/S12032-023-02280-7. - DOI - PubMed
    1. Sonkin D, Thomas A, Teicher BA. Cancer treatments: Past, present, and future. Cancer Genet. 2024;286–287:18–24. doi: 10.1016/J.CANCERGEN.2024.06.002. - DOI - PMC - PubMed
    1. Ramón y Cajal S, Sesé M, Capdevila C, et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl) 2020;98:161–77. doi: 10.1007/S00109-020-01874-2. - DOI - PMC - PubMed

LinkOut - more resources